Simeon George, MD
Board Member

Simeon has served on our Board of Directors since Xap’s founding. Dr. George joined SR One in 2007 and is CEO of the fund. He earned his M.D. and M.B.A. from the University of Pennsylvania School of Medicine / Wharton and B.A. from Johns Hopkins University. Previously, he worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Simeon led SR One’s investments in several marquee deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB, acquired by Sanofi for $3.7bn), Turning Point Therapeutics (TPTX, acquired by BMS for $4.1BN), Design Therapeutics (DSGN), Progyny (PGNY), and he co-founded both Nkarta Therapeutics (NKTX) and Arcellx (ACLX).